ALBUQUERQUE, N.M. & SOMERSET, N.J.--(BUSINESS WIRE)--Oso Biopharmaceuticals Manufacturing, LLC (“Oso Biopharmaceuticals”) and Catalent Pharma Solutions today jointly announced the completion of the purchase of Catalent’s Albuquerque, New Mexico sterile injectables manufacturing business. Terms of the transaction, which became effective May 17, were not disclosed.
The Albuquerque business provides cGMP glass vial filling and lyophilization services for injectable drugs and biologics that are either approved for commercial marketing or in clinical development. Oso Biopharmaceuticals will retain all employees associated with the business and continue to serve all existing customers in North America and Europe.
Dr. Stuart Rose, Chief Executive Officer and President of Oso Biopharmaceuticals, said, “We are delighted to have been successful in acquiring Catalent's sterile injectables business based in Albuquerque. It fits exceedingly well with our strategy to build a world class, high quality contract manufacturing company. We will work tirelessly with the talent pool in Albuquerque to meet the highest demands and expectations of our global customer base.”
Altaris Capital Partners, LLC (“Altaris”), a healthcare investment firm, collaborated with Oso Biopharmaceuticals and provided capital for the transaction.
Richard Yarwood, Group President of Sterile Technologies for Catalent, said, “We are pleased to have completed this planned step in the evolution of our Sterile Technologies business. We are also pleased that Oso Biopharmaceuticals has acquired this business, as we expect they will continue to provide the facility’s customers the high degree of quality and compliance they have received in the past. We also appreciate the commitment Oso Biopharmaceuticals has demonstrated to the future of the business, and to the dedicated employees at the site.”
About Oso Biopharmaceuticals
Oso Biopharmaceuticals Manufacturing, LLC is a contract manufacturing company focused on providing a superior level of service to customers. With an emphasis on the production of injectable pharmaceutical products that require special or complex handling, Oso Biopharmaceuticals understands that attention to detail and service levels are a priority for its clients.
Altaris Capital Partners, LLC is an investment firm focused exclusively on companies operating in the healthcare industry. Altaris is based in New York and has more than $750 million of assets under management. For more information, please visit www.altariscap.com.
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is one of the leading providers of advanced technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 10,000 at more than 30 facilities worldwide and generates more than $1.7 billion of annual revenue. For more information, visit www.catalent.com.
Catalent Pharma Solutions
Cornell Stamoran, 732-537-6408
Oso Biopharmaceuticals Manufacturing, LLC
Dr. Stuart Rose, 505-923-2108
Source: Oso Biopharmaceuticals Manufacturing, LLC and Catalent Pharma Solutions